Neoadjuvant Nivolumab Plus Ipilimumab Shows Trend Towards Long-Term Clinical Benefit versus Chemotherapy in Patients with Resectable NSCLC By Ogkologos - February 24, 2025 805 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors Adding Belzutifan to Pembrolizumab Prolongs DFS After Nephrectomy in Patients with ccRCC at Increased Risk for Recurrence Aiming to Improve Cancer Prevention, ESMO Calls for Strong Policy Measures to Fight the Tobacco Epidemic in Feedback on the EU Tobacco Products and... MOST POPULAR Zanidatamab Demonstrates Meaningful Clinical Benefit with a Manageable Safety Profile in... June 7, 2023 Sen. Amy Klobuchar Announces Breast Cancer Diagnosis, Urges Women Not to... September 10, 2021 Malaria Vaccine Approved by W.H.O. Could Save Tens Of Thousands Of... October 7, 2021 2020 Cancer Incidence and Mortality in EU-27 Countries July 24, 2020 Load more HOT NEWS Woman Who Lost Husband to Male Breast Cancer Goes on Road... FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma Καρκίνος και Κορωνοϊός (COVID-19) ΜΕΡΟΣ Α NCI-MATCH Update: More Labs, New Arms, and Initial Findings
